Michael J Corbel
Overview
Explore the profile of Michael J Corbel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
567
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beresford N, Martino A, Feavers I, Corbel M, Bai X, Borrow R, et al.
Vaccine
. 2017 Apr;
35(28):3598-3606.
PMID: 28408122
A physicochemical and immunological study of the stability of three different meningococcal (Men) ACWY conjugate vaccines was performed to evaluate any patterns of serogroup oligo- or polysaccharide-specific or carrier protein-specific...
2.
Feodorova V, Sayapina L, Corbel M, Motin V
Emerg Microbes Infect
. 2015 Jun;
3(12):e86.
PMID: 26038506
In response to the epidemiological situation, live attenuated or killed vaccines against anthrax, brucellosis, cholera, glanders, plague and tularemia were developed and used for immunization of at-risk populations in the...
3.
Ho M, Markey K, Rigsby P, Hockley J, Corbel M
Vaccine
. 2010 Nov;
29(3):512-8.
PMID: 21055496
The WHO First International Reference Preparation for BCG vaccine is over forty years old and is no longer available for distribution due to stock depletion and its significant loss of...
4.
Markey K, Ho M, Choudhury B, Seki M, Ju L, Castello-Branco L, et al.
Vaccine
. 2010 Aug;
28(43):6964-9.
PMID: 20732463
Current methods for the identification of BCG vaccine in quality control settings involve acid-fast staining with microscopic examination. However, this method is unable to distinguish the many different sub-strains of...
5.
Feodorova V, Corbel M
Expert Rev Vaccines
. 2009 Dec;
8(12):1721-38.
PMID: 19943765
The potential application of Yersinia pestis for bioterrorism emphasizes the urgent need to develop more effective vaccines against airborne infection. The current status of plague vaccines has been reviewed. The...
6.
Corbel M, Cortes Castillo M
Expert Rev Vaccines
. 2009 Oct;
8(10):1439-49.
PMID: 19803764
Biosimilarity is a significant issue for vaccines and a reasonable approach to this could facilitate licensing of follow-on products of similar design. However, the definitions and guideline criteria developed for...
7.
Mawas F, Ho M, Corbel M
Expert Rev Vaccines
. 2008 Dec;
8(1):77-90.
PMID: 19093775
The success of the immunization programs against Haemophilus influenzae type b and, more recently, Streptococcus pneumoniae in developed and some developing countries has demonstrated that invasive disease caused by these...
8.
Gaines-Das R, Ochiai M, Douglas-Bardsley A, Asokanathan C, Horiuchi Y, Rigsby P, et al.
Hum Vaccin
. 2008 Sep;
5(3):166-71.
PMID: 18758243
All current acellular pertussis vaccines (ACVs) contain detoxified pertussis toxin (PT) as a major component. An essential part of the safety evaluation of these vaccines, required by regulatory authorities, is...
9.
Ho M, Markey K, Rigsby P, Jensen S, Gairola S, Seki M, et al.
Vaccine
. 2008 Jul;
26(36):4754-7.
PMID: 18586063
As part of the World Health Organisation (WHO) initiative to update the current requirements for BCG vaccine a collaborative study was carried out to establish the robustness, reproducibility and the...
10.
Corbel M, Das R, Lei D, Xing D, Horiuchi Y, Dobbelaer R
Vaccine
. 2008 Mar;
26(16):1913-21.
PMID: 18336960
This report reflects the discussion and conclusions of a WHO group of experts from National Regulatory Authorities (NRAs), National Control Laboratories (NCLs), vaccine industries and other relevant institutions involved in...